Holen Sie sich die Stockscreener-App
1.64
6.49%
0.10
Handel nachbörslich:
1.64
Schlusskurs vom Vortag:
$1.54
Offen:
$1.55
24-Stunden-Volumen:
7.75M
Relative Volume:
0.88
Marktkapitalisierung:
$492.14M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-1.0933
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
+13.10%
1M Leistung:
+27.13%
6M Leistung:
+1.86%
1J Leistung:
-23.19%
1-Tages-Spanne:
$1.535
$1.69
1-Wochen-Bereich:
$1.45
$1.71
52-Wochen-Spanne:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Vergleichen Sie PACB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.64 | 462.13M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
126.35 | 220.16B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.84 | 157.03B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
400.69 | 154.21B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.97 | 119.08B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.49 | 46.93B | 5.69B | 4.15B | 623.10M | 6.95 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Is it the right time to buy Pacific Biosciences of California Inc. stockBuild a winning investment portfolio - jammulinksnews.com
What is Pacific Biosciences of California Inc. company’s growth strategyMaximize your portfolio’s growth potential - jammulinksnews.com
Is Pacific Biosciences of California Inc. a growth stock or a value stockCapitalize on momentum-driven investment opportunities - jammulinksnews.com
How does Pacific Biosciences of California Inc. generate profit in a changing economyCapitalize on proven trading setups - jammulinksnews.com
Why is Pacific Biosciences of California Inc. stock attracting strong analyst attentionBuild wealth steadily with smart stock selection - jammulinksnews.com
How strong is Pacific Biosciences of California Inc. company’s balance sheetInvest smarter with expert stock recommendations - jammulinksnews.com
What are analysts’ price targets for Pacific Biosciences of California Inc. in the next 12 monthsRealize exceptional returns through smart trading - jammulinksnews.com
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
What makes Pacific Biosciences of California Inc. stock attractive to long term investorsExplosive capital appreciation - jammulinksnews.com
Pacific Biosciences shares rise 1.30% premarket after announcing significant advancement in genomic sequencing. - AInvest
Pacific Biosciences of California Inc. Stock Analysis and ForecastExplosive returns - PrintWeekIndia
PacBio (PACB) Technology Powers Significant Genomic Research in Arab Populations | PACB Stock News - GuruFocus
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand - Yahoo.co
Publication spotlight: How Kinnex long-read RNA sequencing wins out over Illumina for transcript-level quantification - PacBio
What analysts say about Pacific Biosciences of California Inc. stockExceptional earning trajectories - Autocar Professional
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Intrinsic Value Is Potentially 41% Above Its Share Price - 富途牛牛
Why PacBio (PACB) Stock Is Up Today - Yahoo Finance
QIAGEN’s New Sequencing Panels Boosts PacBio Expansion - StocksToTrade
Pacific Biosciences: The Shift To Razor-Blade Economics Could Be A Game Changer - Seeking Alpha
PacBio Joins 1000 Genomes Long Read Sequencing Project to Enhance Human Genomics Research - Nasdaq
PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio - Yahoo Finance
Is Pacific Biosciences of California Inc. a good long term investmentPhenomenal wealth increase - Autocar Professional
QIAGEN Expands NGS Portfolio with QIAseq xHYB Long Read Panels - AInvest
What drives Pacific Biosciences of California Inc. stock priceRapid capital growth - jammulinksnews.com
PacBio (PACB) Collaborates with Qiagen for Enhanced Genomic Insi - GuruFocus
QIAGEN launches long-read sequencing panels for complex genomic regions By Investing.com - Investing.com Canada
PACB Stock Rally: Bullish Signs or Temporary Spike? - StocksToTrade
Published on: 2025-07-22 17:54:31 - jammulinksnews.com
DNA Sequencing Leader PacBio Sets Q2 2025 Earnings Release Date: What Analysts Are Watching - Stock Titan
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know - Yahoo.co
How long-read sequencing uncovers hitchhikers of the genomic galaxy in parasitic fungi - PacBio
Pacific Biosciences Stock Jumps Amid Strategic Acquisitions - StocksToTrade
Pacific Biosciences Sees Stock Uptick Following Strategic Moves - timothysykes.com
Chromosome-level genome assembly with telomeric repeats at scaffold ends for Rhabdosargus sarba - Nature
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):